Pharma vets with Genentech connection band together to launch new immunotherapy startup, though details are scant
On Thursday, three researchers announced they had started up a new immunotherapy biotech called LTZ Therapeutics, short for “Lift To Zenith,” and launched with a modest raise they’re calling a “pre-Series A.” In total, it’s a $17 million round, led by K2 Venture Partners and assisted by Qiming Venture Partners and Tigermed.
There are few details so far, but the company is making an initial impression thanks to a direct connection to Genentech.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters